DANBURY, Conn., Sept. 1 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that Linjeta™ (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel's most advanced product candidate. The change follows FDA's review and acceptance of Linjeta™ as an alternative name for Biodel's more-rapid-acting insulin formulation that is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Application date of October 30, 2010.
Dr. Errol De Souza, Biodel 's president and chief executive officer, stated: "Today's news reflects the continued progress of the Linjeta™ new drug application through FDA review and is an important milestone in our effort to commercialize this new drug candidate."
About Biodel Inc. Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for Linjeta™, its most advanced product candidate, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com. Contact:The Trout Group LLCSeth D. Lewis, +1-646-378-2952
|SOURCE Biodel Inc.|
Copyright©2010 PR Newswire.
All rights reserved